Circulation. 2002;106:1282-1287
Published online before print August 12, 2002, doi: 10.1161/01.CIR.0000027816.54430.96
Published online before print August 12, 2002, doi: 10.1161/01.CIR.0000027816.54430.96
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:1282.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice
From the Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia.
Correspondence to Domenico Praticò, MD, Center for Experimental Therapeutics, Room 812, Biomedical Research Bldg 2/3, University of Pennsylvania, Philadelphia, PA 19104. E-mail domenico{at}spirit.gcrc.upenn.edu
Background— Atherosclerosis is a complex vascular inflammatory disease. Low-dose aspirin is a mainstay in the prevention of vascular complications of atherosclerosis. We wished to determine the effect of low-dose aspirin on vascular inflammation, plaque composition, and atherogenesis in LDL receptor–deficient mice fed a high fat diet.
Methods and Results— In LDL receptor–deficient mice fed a high fat diet compared with control mice, low-dose aspirin induced a significant decrease in circulating levels and vascular formation of soluble intercellular molecule-1, monocyte chemoattractant protein-1, tumor necrosis factor-
, interleukin-12p 40, without affecting lipid levels. This was associated with significant reduction of the nuclear factor 
B activity in the aorta. Low-dose aspirin also significantly reduced the extent of atherosclerosis. Finally, aortic vascular lesions of the aspirin-treated animals showed 57% reduction (P<0.05) in the amount of macrophage cells, 77% increase in smooth muscle cells (P<0.05), and 23% increase in collagen (P<0.05).
Conclusions— Our results suggest that in murine atherosclerosis, low-dose aspirin suppresses vascular inflammation and increases the stability of atherosclerotic plaques, both of which, together with its antiplatelet activity, contribute to its antiatherogenic effect. We conclude that low-dose aspirin might be rationally evaluated in the progression and evolution of human atherosclerotic plaque.
Key Words: atherosclerosis • aspirin • inflammation • plaque
This article has been cited by other articles:
 |
|
 |
|
  L. Zhu, T. J. Stalker, K. P. Fong, H. Jiang, A. Tran, I. Crichton, E. K. Lee, K. B. Neeves, S. F. Maloney, H. Kikutani, et al. Disruption of SEMA4D Ameliorates Platelet Hypersensitivity in Dyslipidemia and Confers Protection Against the Development of Atherosclerosis Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1039 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Largo, M. J. Martinez-Calatrava, O. Sanchez-Pernaute, M. E. Marcos, J. Moreno-Rubio, C. Aparicio, J. Egido, and G. Herrero-Beaumont Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H268 - H276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bulckaen, G. Prevost, E. Boulanger, G. Robitaille, V. Roquet, C. Gaxatte, G. Garcon, B. Corman, P. Gosset, P. Shirali, et al. Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1562 - H1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tailor, K. C. Wood, J. L. Wallace, R. D. Specian, and D. N. Granger Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3636 - H3642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Shibata, S. Maeda, Y. Hikiba, A. Yanai, T. Ohmae, K. Sakamoto, H. Nakagawa, K. Ogura, and M. Omata Cutting Edge: The I{kappa}B Kinase (IKK) Inhibitor, NEMO-Binding Domain Peptide, Blocks Inflammatory Injury in Murine Colitis J. Immunol., September 1, 2007; 179(5): 2681 - 2685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J.-M. Herbert, and T. F. Luscher Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease Vascular Medicine, May 1, 2007; 12(2): 113 - 122. [Abstract] [PDF]
|
|
|
|
 |
|
 L. A. Stark, K. Reid, O. J. Sansom, F. V. Din, S. Guichard, I. Mayer, D. I. Jodrell, A. R. Clarke, and M. G. Dunlop Aspirin activates the NF-{kappa}B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer Carcinogenesis, May 1, 2007; 28(5): 968 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Cyrus, Y. Yao, T. Ding, J. M. Dogne, and D. Pratico Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice Blood, April 15, 2007; 109(8): 3291 - 3296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yao, W. J. Walsh, W. R. McGinnis, and D. Pratico Altered Vascular Phenotype in Autism: Correlation With Oxidative Stress. Arch Neurol, August 1, 2006; 63(8): 1161 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Lopez-Franco, P. Hernandez-Vargas, G. Ortiz-Munoz, G. Sanjuan, Y. Suzuki, L. Ortega, J. Blanco, J. Egido, and C. Gomez-Guerrero Parthenolide Modulates the NF-{kappa}B-Mediated Inflammatory Responses in Experimental Atherosclerosis Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1864 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tancevski, A. Wehinger, W. Schgoer, P. Eller, S. Cuzzocrea, B. Foeger, J. R. Patsch, and A. Ritsch Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice FASEB J, July 1, 2006; 20(9): 1328 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zuccollo, C. Shi, R. Mastroianni, K. A. Maitland-Toolan, R. M. Weisbrod, M. Zang, S. Xu, B. Jiang, J. M. Oliver-Krasinski, A. J. Cayatte, et al. The Thromboxane A2 Receptor Antagonist S18886 Prevents Enhanced Atherogenesis Caused by Diabetes Mellitus Circulation, November 8, 2005; 112(19): 3001 - 3008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tang, T. Cyrus, Y. Yao, L. Vocun, and D. Pratico Involvement of Thromboxane Receptor in the Proatherogenic Effect of Isoprostane F2{alpha}-III: Evidence From Apolipoprotein E- and LDL Receptor-Deficient Mice Circulation, November 1, 2005; 112(18): 2867 - 2874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Wu, J.-Y. Liou, and K. Cieslik Transcriptional Control of COX-2 via C/EBP{beta} Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 679 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vinals, I. Bermudez, G. Llaverias, M. Alegret, R. M. Sanchez, M. Vazquez-Carrera, and J. C. Laguna Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages Cardiovasc Res, April 1, 2005; 66(1): 141 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kojda Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity? Cardiovasc Res, November 1, 2004; 64(2): 192 - 194. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Boord, K. Maeda, L. Makowski, V. R. Babaev, S. Fazio, M. F. Linton, and G. S. Hotamisligil Combined Adipocyte-Macrophage Fatty Acid-Binding Protein Deficiency Improves Metabolism, Atherosclerosis, and Survival in Apolipoprotein E-Deficient Mice Circulation, September 14, 2004; 110(11): 1492 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Torsney, U. Mayr, Y. Zou, W. D. Thompson, Y. Hu, and Q. Xu Thrombosis and Neointima Formation in Vein Grafts Are Inhibited by Locally Applied Aspirin Through Endothelial Protection Circ. Res., June 11, 2004; 94(11): 1466 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhang, J. Ma, M. Xia, H. Zhu, and W. Ling Mild Hyperhomocysteinemia Induced by Feeding Rats Diets Rich in Methionine or Deficient in Folate Promotes Early Atherosclerotic Inflammatory Processes J. Nutr., April 1, 2004; 134(4): 825 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Monaco and E. Paleolog Nuclear factor {kappa}B: a potential therapeutic target in atherosclerosis and thrombosis Cardiovasc Res, March 1, 2004; 61(4): 671 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Belton, A. Duffy, S. Toomey, and D. J. Fitzgerald Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis Circulation, December 16, 2003; 108(24): 3017 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation Circulation, October 21, 2003; 108(90161): III-22 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D Timmis Plaque stabilisation in acute coronary syndromes: clinical considerations Heart, October 1, 2003; 89(10): 1268 - 1272. [Full Text] [PDF]
|
|
|
|
|
|
S.-P. Yang, L.-J. Ho, Y.-L. Lin, S.-M. Cheng, T.-P. Tsao, D.-M. Chang, Y.-L. Hsu, C.-Y. Shih, T.-Y. Juan, and J.-H. Lai Carvedilol, a new antioxidative {beta}-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-{kappa}B activity Cardiovasc Res, September 1, 2003; 59(3): 776 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Grosser and H. Schroder Aspirin Protects Endothelial Cells From Oxidant Damage Via the Nitric Oxide-cGMP Pathway Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1345 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schachter Review: Lipid lowering drugs, inflammation and cardiovascular disease The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 178 - 182. [Abstract] [PDF]
|
|